Researchers in Prof. Karl Deisseroth's laboratory have engineered versatile, virus-based constructs that are driven by neuronal activity to either label or optogenetically control those active neurons.
Stanford researchers at the Jaramillo, Nørskov, and Cargnello Labs have developed an improved system to generate NH3 (ammonia) from N2 and H2O via a low-pressure, electro-thermochemical, sustainable alternative to the conventional Haber-Bosch p
Stanford researchers have developed a method that can tune the ratio between reversible (RE) and irreversible (IRE) electroporation through waveform adjustments.
Drs. Purvesh Khatri and Timothy Sweeney at Stanford have identified a set of three genes that can be used to diagnose active tuberculosis (TB) and distinguish active TB from latent TB or other diseases. TB is a worldwide public health problem.
Researchers at Stanford have developed a ferumoxytol-based dual-modality imaging probe that allows for long-term stem cell tracking through MRI and early diagnosis of cell apoptosis through simultaneous fluorescence imaging.
Richard Zare's lab at Stanford University has developed a ground-breaking drug release system in which injected medication can be controlled externally with excellent spatial, temporal, and dosage control.
Researchers in Dr. Richard Zare's lab have developed solid lipid nanoparticles (SLNPs) that provide sustained in vivo delivery of small interfering RNAs (siRNAs). siRNAs can silence genes responsible for disease, which makes them promising tools for gene therapy.
A Stanford researcher leverages common wafer manufacturing processes to optimize the performance of photonic bandgap (PBG) crystals for a variety of applications.
Stanford researchers have developed a liquid microjet which provides the first nanoflow capability for serial femtosecond crystallography (SFX) with x-ray lasers.
Researchers in Prof. Monte Winslow's laboratory have developed two viable, fertile transgenic mouse strains that enable rapid, simple generation of loss-of-function models with CRISPR/Cas9 mediated genome editing in vivo or ex vivo.
Stanford researchers have proposed antibody-based reduction of Neuromedin (NMU) signaling as a therapeutic strategy to improve glucose metabolism in multiple physiological or disease states, including obesity, diabetes, and cancer where NMU levels are elevated.
Stanford researchers have patented a photosynthetic system using a cyanobacterium solution that can be delivered to ischemic tissues, where blood flow is insufficient. This addresses a major clinical problem for patients with heart and vascular diseases.